Skip to content
Credit reportVerdict and grounds
Made on 19-11-2026 at 03:35
Reference CK-0432850028-20261119

PHARMA PLUS

ActivePrivate limited company0432.850.028Rue Alfred Dendal 192, 7300 Boussu
Retail sale of pharmaceutical products (NACE 47730) · founded in 1987 · 5 employees on 31-12-2025 · 4th largest company by equity in Boussu, Wholesale and retail trade sector

Sources: the KBO register on 19-11-2026; the National Bank, 2025 annual accounts filed on 12-05-2026; the Belgian Official Gazette, latest deed of 04-08-2026.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 40,303 micro companies in the retail trade sector (NACE 47) is 0.6%.
Gross margin
€248,353
▼ 58.8% against 2024
Net result
€15,884
▼ 79.7% against 2024
Equity
€876,038
▲ 1.8% against 2024
Cash
€5,375
▼ 1.9% against 2024

Grounds

the facts the verdict rests on, each with its source
  1. In 2025, PHARMA PLUS closed with a net profit of €15,884.Annual accounts 2025 page 2
  2. Equity stands at €876,038, or 85.2% of the balance sheet total of €1.0m. That is more than 59% of the 2,455 companies in the retail trade sector (NACE 47).Annual accounts 2025 page 2
  3. The last five annual accounts came in on time. The 2025 accounts were filed 80 days before the end of the term.National Bank, filing of 12-05-2026 page 5
  4. (0405.366.364) holds all the shares. Its equity stood at €33.0m on 31-12-2025. That parent has 34 holdings.Annual accounts 2025 of page 4

Representation

Checked did not find the signing rule in the deeds it read.

Ownership

(0405.366.364) holds all the shares. Its equity stood at €33.0m on 31-12-2025.

Annual accounts 2025 of

PHARMA PLUS · 0432.850.028 · credit report of 19-11-2026Page 1 of 6
PHARMA PLUS0432.850.028 · report of 19-11-2026

Financial situation

Annual accounts 2021 to 2025, as filed with the National Bank

Gross margin and net resultin €m

20210.420220.520230.520240.620250.220210.0520220.0920230.0520240.0820250.02
gross marginnet result

Equity and debtsin €m

202120222023202420250.90.2
equitydebts

Cashin €m

20210.0120220.0120230.0120240.0120250.01
on the balance sheet date
Financial year20212022202320242025Trend
Results
Gross margin€436,803€483,482€453,821€602,949€248,353
Operating result€75,885€125,879€70,529€95,214€12,076
Net result€54,870€92,689€50,938€78,352€15,884
Balance sheet at the closing date
Equity€1.0m€1.1m€781,803€860,154€876,038
Debts€190,287€226,450€296,324€189,118€152,303
Debts due within one year€190,287€226,450€296,324€189,118€152,303
Cash€6,981€13,408€11,810€5,478€5,375
Balance sheet total€1.2m€1.3m€1.1m€1.0m€1.0m
Operations
Employees in full-time equivalents6.55.65.94.24.1
Ratios
Solvency84.1%82.9%72.5%82.0%85.2%
Liquidity2.983.311.864.315.13

Source: Annual accounts 2025, full format, filed on 12-05-2026 (2026-00111137); Annual accounts 2024, full format, filed on 17-06-2025 (2025-00144634); Annual accounts 2021 to 2023, filed from 07-06-2022 to 12-06-2024 (2022-20051853, 2023-00123324, 2024-00127224).

The operating result of 2025 is 87% lower than in 2024.

Debts fell by €36,815 in 2025.

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

PHARMA PLUS · 0432.850.028 · credit report of 19-11-2026Page 2 of 6
PHARMA PLUS0432.850.028 · report of 19-11-2026

Board, signature and ownership

Position on 19-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

Checked did not find the signing rule in the deeds it read.

Board

four directors in office
Chair of the board and directorappointed by deed of 14-12-2022
deed of 14-12-2022
Director and managing directorsince 22-12-2020
term without a fixed enddeed of 25-03-2021
Directorappointed by deed of 04-08-2026
deed of 04-08-2026
Director and managing directorappointed by deed of 25-03-2021
deed of 25-03-2021

also sits on the boards of 45 other companies. also sits on the boards of 31 other companies. also sits on the boards of 3 other companies.

Ownership and group

Shareholders

(0405.366.364) holds all the shares. Its equity stood at €33.0m on 31-12-2025.

Annual accounts 2025 of

Board changes

resigns. appointed. acts as permanent representative. General meeting of 19-05-2026.

Gazette, deed 26099510

New chair of the board. appointed, resigned. and act as permanent representatives. Board meeting of 01-09-2022.

Gazette, deed 22147566

Issue of 17,000 shares. changes role from director to managing director. appointed as chair. General meeting of 22-12-2020.

Gazette, deed 21037955

resigns as managing director. and (managing director) appointed. acts as permanent representative. General meeting of 29-02-2016.

Gazette, deed 16038448

(managing director and chair of the board) and (director) reappointed. General meeting of 22-04-2011.

Gazette, deed 11186793
PHARMA PLUS · 0432.850.028 · credit report of 19-11-2026Page 3 of 6
PHARMA PLUS0432.850.028 · report of 19-11-2026

Group

has 34 holdings (2025 accounts).

Country CompanyYear Equity Result
Belgium 34
BE PHARMA PLUSthis company2025 €876,038 result €15,884
BE 2025 €2.0m result €70,063
BE 2025 €2.0m result €70,773
BE 2025 €1.8m result €27,487
BE 2025 €1.5m result €39,635
BE 2025 €1.3m result €31,345
BE 2025 €1.2m result -€21,813
BE 2025 €1.2m result €68,611
BE 2025 €1.2m result €6,589
BE 2025 €1.2m result -€87,206
BE 2025 €1.2m result €52,938
BE 2025 €1.1m result €49,219
BE 2025 €1.1m result €74,220
BE 2025 €913,124 result €83,390
BE 2025 €908,418 result €66,552
BE 2025 €875,529 result €21,018
BE 2025 €619,306 result €28,974
BE 2025 €573,958 result €56,725
BE 2025 €556,284 result €35,837
BE 2025 €538,245 result €40,263
BE 2025 €485,489 result €51,818
BE 2025 €483,944 result €67,222
BE 2025 €463,825 result €46,725
BE 2025 €437,140 result €23,964
BE 2025 €426,866 result €31,577
BE 2025 €368,033 result €15,209
BE 2025 €358,217 result €26,706
BE 2025 €351,857 result €43,562
BE 2025 €331,470 result -€22,880
BE dissolved2026 €265,436 result -€829

The dossier shows 4 more holdings.

Source: List of holdings in the 2025 accounts of . Every holding stands with its own latest accounts.

PHARMA PLUS · 0432.850.028 · credit report of 19-11-2026Page 4 of 6
PHARMA PLUS0432.850.028 · report of 19-11-2026

Events and comparison

The last 24 months, newest first

resigns. appointed. acts as permanent representative. General meeting of 19-05-2026.

Gazette, deed 26099510

Annual accounts 2025 filed, 80 days before the deadline.

NBB filing

Annual accounts 2024 filed, 44 days before the deadline.

NBB filing

Registered in the Peppol Directory. Reachable for e-invoices through 0208:0432850028.

Liquidity more than doubled. The current ratio rises from 1.86 to 4.31. Short-term debt falls from €296,324 to €189,118.

Financial

Comparable companies, two years later

In July 2024, 17,047 companies had the same profile as PHARMA PLUS has now: micro, 20 years or older, solvency 30% or more and a profit under 5% of the balance sheet. Two years later 94.3% were still trading, 5.2% had stopped another way and 0.5% had gone bankrupt.

still trading 94.3% stopped another way 5.2% bankrupt 0.5%

In 2025, PHARMA PLUS had a lower net result than 66% of the 2,456 companies in the retail trade sector (NACE 47).

Other findings

Peppol

Reachable for e-invoices since 06-06-2025, under 0208:0432850028.

Sanctions lists

Staff

5 employees on 31-12-2025, 4.1 full-time equivalents on average over the year.

PHARMA PLUS · 0432.850.028 · credit report of 19-11-2026Page 5 of 6
PHARMA PLUS0432.850.028 · report of 19-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units19-11-2026KBO 0432.850.028
National Bank of BelgiumAnnual accounts 2025, full format12-05-20262026-00111137
National Bank of BelgiumAnnual accounts 2024, full format17-06-20252025-00144634
National Bank of BelgiumAnnual accounts 2021 to 202307-06-2022 to 12-06-20242022-20051853, 2023-00123324, 2024-00127224
Belgian Official GazetteBoard04-08-2026deed 26099510
Belgian Official GazetteBoard14-12-2022deed 22147566
Belgian Official GazetteBoard25-03-2021deed 21037955
Peppol DirectoryRegistration for e-invoices06-06-20250208:0432850028
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name16-11-2026no match
CheckedChecked score, bankruptcy probability, credit, comparable companies18-11-2026bankruptcy model of 2 October 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 18-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Payment terms. Supplier credit is the debt to suppliers divided by the year's purchases, times 365. Customer credit is the same for what customers still owe, against turnover.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

PHARMA PLUS · 0432.850.028 · credit report of 19-11-2026Page 6 of 6